Merck & Co., Inc. (ETR:6MK)
Germany · Delayed Price · Currency is EUR | Market Cap | 253.91B +5.7% |
| Revenue (ttm) | 55.37B +1.3% |
| Net Income | 15.55B +6.6% |
| EPS | 6.20 +8.0% |
| Shares Out | n/a |
| PE Ratio | 16.33 |
| Forward PE | 23.56 |
| Dividend | 2.86 (2.77%) |
| Ex-Dividend Date | Dec 15, 2025 |
| Volume | 8,002 |
| Average Volume | 3,337 |
| Open | 100.60 |
| Previous Close | 102.00 |
| Day's Range | 99.60 - 103.60 |
| 52-Week Range | 65.50 - 103.80 |
| Beta | 0.30 |
| RSI | 67.98 |
| Earnings Date | Feb 3, 2026 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B... [Read more]
Financial Performance
In 2025, Merck & Co.'s revenue was $65.01 billion, an increase of 1.31% compared to the previous year's $64.17 billion. Earnings were $18.25 billion, an increase of 6.64%.
Financial numbers in USD Financial StatementsNews
Dow Movers: GS, MRK
In early trading on Friday, shares of Merck topped the list of the day's best performing Dow Jones Industrial Average components, trading up 3.1%. Year to date, Merck registers a 16.8% gain. And the w...
Is Merck (MRK) a Buy as Wall Street Analysts Look Optimistic?
Based on the average brokerage recommendation (ABR), Merck (MRK) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this hig...
Avantis Responsible U.S. Equity ETF Buys 162 Shares of Merck & Co Inc (MRK)
Avantis Responsible U.S. Equity ETF Buys 162 Shares of Merck & Co Inc (MRK)
American Century U.S. Quality Growth ETF Sells 389,784 Shares of Merck & Co Inc (MRK)
American Century U.S. Quality Growth ETF Sells 389,784 Shares of Merck & Co Inc (MRK)
American Century U.S. Quality Value ETF Sells 28,574 Shares of Merck & Co Inc (MRK)
American Century U.S. Quality Value ETF Sells 28,574 Shares of Merck & Co Inc (MRK)
American Century Large Cap Equity ETF Buys 1,442 Shares of Merck & Co Inc (MRK)
American Century Large Cap Equity ETF Buys 1,442 Shares of Merck & Co Inc (MRK)
Xtrackers S&P 500 Value Scored & Screened ETF Sells 633 Shares of Merck & Co Inc (MRK)
Xtrackers S&P 500 Value Scored & Screened ETF Sells 633 Shares of Merck & Co Inc (MRK)
Xtrackers MSCI USA Selection Equity ETF Sells 9,344 Shares of Merck & Co Inc (MRK)
Xtrackers MSCI USA Selection Equity ETF Sells 9,344 Shares of Merck & Co Inc (MRK)
French vaccine maker Sanofi ousts CEO Paul Hudson with Merck boss to take over
French drugmaker Sanofi ousted CEO Paul Hudson on Thursday, ending a six-year tenure marked by a stalled drive to replace blockbuster drugs going off patent and rising pressure from US anti-vaccine po...
Merck: Keytruda Remains Resilient Despite LOE Risks - Buy Upon Correction
New KEYTRUDA indications are expected to preserve Merck's top line. Click here to read why MRK stock remains a great buy upon correction.
Xtrackers MSCI Kokusai Equity ETF Sells 459 Shares of Merck & Co Inc (MRK)
Xtrackers MSCI Kokusai Equity ETF Sells 459 Shares of Merck & Co Inc (MRK)
Xtrackers S&P 500 Scored & Screened ETF Buys 5,267 Shares of Merck & Co Inc (MRK)
Xtrackers S&P 500 Scored & Screened ETF Buys 5,267 Shares of Merck & Co Inc (MRK)
Xtrackers MSCI USA Climate Action Equity ETF Sells 203 Shares of Merck & Co Inc (MRK)
Xtrackers MSCI USA Climate Action Equity ETF Sells 203 Shares of Merck & Co Inc (MRK)
These 32 favorite stocks signal the bull market is running on fumes
The S&P 500 sectors that top investment newsletters currently like most are strongest at market peaks.
Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium.
Goldman Sachs MarketBeta U.S. 1000 Equity ETF Sells 712 Shares of Merck & Co Inc (MRK)
Goldman Sachs MarketBeta U.S. 1000 Equity ETF Sells 712 Shares of Merck & Co Inc (MRK)
Goldman Sachs MarketBeta U.S. Equity ETF Buys 4,741 Shares of Merck & Co Inc (MRK)
Goldman Sachs MarketBeta U.S. Equity ETF Buys 4,741 Shares of Merck & Co Inc (MRK)
FDA Approves Merck's Keytruda And Keytruda Qlx For Platinum-Resistant Ovarian Cancer
KENILWORTH (NJ) (dpa-AFX) - Merck & Co Inc. (MRK) on Wednesday said the U.S. Food and Drug Administration has approved Keytruda and Keytruda Qlx, a subcutaneous formulation of Keytruda, in combina...
FDA Approves Merck's KEYTRUDA for Advanced Ovarian Cancer Treatment
FDA Approves Merck's KEYTRUDA for Advanced Ovarian Cancer Treatment
KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab ...
KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) a...
Insider Sell Alert: Dean Li Sells Shares of Merck & Co Inc (MRK)
Insider Sell Alert: Dean Li Sells Shares of Merck & Co Inc (MRK)
FDA Approves Merck's Keytruda for New Cancer Indications (MRK)
FDA Approves Merck's Keytruda for New Cancer Indications (MRK)
Merck's Keytruda gains additional indications for ovarian, fallopian tube carcinoma
FDA approves Merck’s Keytruda for PD‑L1+ platinum‑resistant ovarian cancers. Read more here.
FDA Approves Merck's Keytruda for Specific Cancer Treatments
FDA Approves Merck's Keytruda for Specific Cancer Treatments